Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry – CLINICAL & TRANSLATIONAL ONCOLOGY

Carcereny, E; Rodriguez-Abreu, D; Lopez, R; Franco, F; Guirado, M; Massuti, B; Cobo, M; Blasco, A; Suay, G; del Barco, E; Ortega, AL; Sala, MA; Cordeiro, P; Bernabé, R; Larriba, JLG; Bosch-Barrera, J; Calzas, J; Casal, J; Padilla, A; Sánchez-Hernandez, A; Provencio, M...

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial – EUROPEAN JOURNAL OF CANCER

Reck, M; Ciuleanu, TE; Schenker, M; Bordenave, S; Cobo, M; Juan-Vidal, O; Reinmuth, N; Richardet, E; Felip, E; Menezes, J; Cheng, Y; Mizutani, H; Zurawski, B; Alexandru, A; Carbone, DP; Lu, S; John, T; Aoyama, T; Grootendorst, DJ; Hu, N; Eccles, LJ; Paz-Ares, LG...

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study – ANNALS OF ONCOLOGY

Passaro, A; Wang, J; Wang, Y; Lee, SH; Melosky, B; Shih, JY; Wang, J; Azuma, K; Juan-Vidal, O; Cobo, M; Felip, E; Girard, N; Cortot, AB; Califano, R; Cappuzzo, F; Owen, S; Popat, S; Tan, JL; Salinas, J; Tomasini, P; Gentzler, RD; William, WN Jr; Reckamp, KL;...

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial – JOURNAL FOR IMMUNOTHERAPY OF CANCER

Carbone, DP; Ciuleanu, TE; Schenker, M; Cobo, M; Bordenave, S; Juan-Vidal, O; Menezes, J; Reinmuth, N; Richardet, E; Cheng, Y; Mizutani, H; Felip, E; Zurawski, B; Alexandru, A; Paz-Ares, L; Lu, S; John, T; Zhang, XQ; Mahmood, J; Hu, N; De, TL; Santi, I; Penrod, JR;...